Tech Company Financing Transactions
FundaMental Pharma Funding Round
FundaMental Pharma closed a $10.3 million Seed funding round on 11/21/2022. Backers included BioGeneration Ventures, Thuja Capital and High-Tech Gründerfonds.
Transaction Overview
Company Name
Announced On
11/21/2022
Transaction Type
Venture Equity
Amount
$10,270,000
Round
Seed
Investors
Proceeds Purpose
The company intends to use the funds to accelerate growth, and expand its development efforts.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Im Neuenheimer Feld 582
Heidelberg, D-69120
DE
Heidelberg, D-69120
DE
Phone
Undisclosed
Website
Email Address
Overview
The FundaMental Pharma Team harnesses the power of this revolutionary discovery of a new drug class to stop loss of brain structure and thus loss of function. FundaMental Pharma GmbH is a neuroscience company with portfolio at the preclinical stage, which was spun out of the Department of Neurobiology at Heidelberg University, Germany. First-in class NMDAR/TRPM4 (N/T) Interface Inhibitors selectively abolish extrasynaptic NMDARs-induced glutamate neurotoxicity but preserve the effects of synaptic NMDARs on neuronal survival and memory. N/T interface inhibition has the potential to stop neurodegeneration, to restore neuronal function, and to maintain brain health. N/T interface inhibitors provide neuroprotection through selective elimination of toxic extra synaptic NMDARs signaling.
Management Team
Browse more venture capital transactions:
Prev: 11/21/2022: Modern Milkman venture capital transaction
Next: 11/21/2022: Diffblue venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on all VC transactions involving tech companies. All VC database entries reported here are derived from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs